Back to search results

Intermittent Fasting for Prostate Cancer Patients on Androgen Deprivation Therapy

This study is looking at whether intermittent fasting (eating only during specific times) is possible for men with prostate cancer who are also receiving androgen deprivation therapy (a treatment that lowers male hormones). The study will also explore if adding a plant-rich diet is feasible. We want to see how many people join the study, how many complete it, and how well they follow the diet. You may be able to join if you are a man at least 18 years old with measurable prostate cancer and are eligible for androgen deprivation therapy. This is a pilot study, meaning it's a small first step to see if a larger study would be worthwhile. The study aims to enroll 30 participants.

Study design
This is an interventional pilot study, meaning participants will receive a specific intervention (intermittent fasting). It aims to enroll 30 male participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure enrollment and drop-out rates over 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06172283

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Recruiting
NAAges 18+InterventionalTreatment
State University of New York at Buffalo
~30 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Intermittent Fasting

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment rate
Measured over 3 years
+1 more outcome measured

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
New York1

Who to contact

Roberto Pili, MD
[email protected]
716-881-8918
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

In order to be eligible for participation in this trial, the subject must:
Be willing and able to provide written informed consent for the trial.
Be male at birth and least 18 years of age on day of signing informed consent.
Have measurable prostate cancer disease and be eligible for androgen deprivation therapy.
Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
Demonstrate adequate organ function (all screening labs should be performed within 10 days of treatment initiation).
Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment.
Subjects must have a life expectancy of at least 6 months.

Exclusion

Has an ECOG performance of 2 or higher.
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the beginning of the treatment.
Has a known additional malignancy that is progressing or requires active treatment.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Has a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging
Has any other medical intervention or condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives.
Is not willing and able to provide written informed consent for the trial.

What this trial measures

  • Enrollment rate3 years

    Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy

  • Drop-out rate3 years

    Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy